Related Experiment Videos
Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1
1Department of Pharmacology and Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Abstract:
The expression of multidrug-resistance (MDR) in breast carcinoma cell line MCF-7/ADR50 is primarily dependent on the transcriptional activation of the MDR1 gene. We now report that MDR in this cell line is partially reversed by the type I cAMP-dependent protein kinase (PKA) inhibitor, 8-Cl-cAMP. MDR1 promoter activity was also regulated through a PKA-dependent pathway and was inhibited by 8-Cl-cAMP, and stimulated by the enantiomeric agonist, SpcAMP[S]. MDR1 promoter activity through an Sp1 response element was stimulated by exogenous Sp1, a factor that we have shown to be activated by PKA. These results indicate that MDR1 promoter activity is linked to the cAMP/PKA signaling pathway, and that PKA antagonists may be useful for reversing the multidrug-resistant phenotype.
Insights
Multidrug-resistance (MDR) in breast cancer cells can be partially reversed by inhibiting the cAMP-dependent protein kinase (PKA) pathway. This suggests PKA antagonists may help overcome MDR in cancer treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Multidrug-resistance (MDR) is a major challenge in breast cancer chemotherapy.
- The MDR1 gene plays a crucial role in the MDR phenotype of breast carcinoma cell line MCF-7/ADR50.
- The cAMP-dependent protein kinase (PKA) signaling pathway is implicated in various cellular processes, including gene expression.
Purpose of the Study:
- To investigate the role of the cAMP/PKA signaling pathway in regulating MDR1 gene expression in MCF-7/ADR50 cells.
- To determine if inhibiting PKA can reverse the multidrug-resistant phenotype.
- To explore the mechanism by which PKA influences MDR1 promoter activity.
Main Methods:
- Utilized the breast carcinoma cell line MCF-7/ADR50.
- Administered the PKA inhibitor 8-Cl-cAMP and the agonist SpcAMP[S].
- Assessed MDR1 promoter activity and the role of Sp1 transcription factor.
Main Results:
- The PKA inhibitor 8-Cl-cAMP partially reversed MDR in MCF-7/ADR50 cells.
- MDR1 promoter activity was regulated by a PKA-dependent pathway, inhibited by 8-Cl-cAMP, and stimulated by SpcAMP[S].
- Exogenous Sp1, activated by PKA, stimulated MDR1 promoter activity via an Sp1 response element.
Conclusions:
- MDR1 promoter activity is directly linked to the cAMP/PKA signaling pathway.
- PKA antagonists show potential for reversing the multidrug-resistant phenotype in breast cancer.
- Targeting the cAMP/PKA pathway could be a novel strategy to enhance chemotherapy efficacy.